Formulation guide · India · Updated August 2026
Short answer: since 9 June 2026 there is no “best dry cough syrup you can buy” in India, because you can no longer buy one off the shelf. Notification G.S.R. 477(E) deleted the word Syrups from item (7) under serial number 13 of Schedule K of the Drugs Rules, 1945, so every syrup formulation is now dispensed against a doctor’s prescription.[1][2]
What is still worth knowing before that consultation is what is actually inside these packs. Eight of the dry-cough brands Indian adults name most often resolve to three real compositions. Several of the packs widely described online as “non-drowsy” contain chlorpheniramine maleate, a first-generation sedating antihistamine. That single fact changes the driving advice, and it is the part almost every listicle gets wrong.
What changed in June 2026, and why it makes brand rankings obsolete
Schedule K of the Drugs Rules, 1945 lists classes of drugs exempted from certain provisions of Chapter IV of the Drugs and Cosmetics Act, 1940, subject to stated conditions. Item (7) under serial number 13 previously included syrups, which is the provision that allowed them to move through relaxed retail channels. The Ministry of Health and Family Welfare, acting under sections 12 and 33 of the Act and after consultation with the Drugs Technical Advisory Board, notified the Drugs (Fifth Amendment) Rules, 2026 as G.S.R. 477(E) on 9 June 2026, omitting that word. The rules came into force on publication in the Official Gazette. The draft had been circulated on 29 December 2025 as G.S.R. 927(E) with a thirty-day comment window.[1][2]
Two consequences follow for anyone reading a page like this one. The choice of product now sits with a prescriber, so a ranked list of brands is advice you cannot act on. And the useful preparation shifts from shopping to describing your cough accurately and understanding the label you will be handed. Our hub page covers the wider decision across both cough types: what the new cough syrup rules changed and how to choose.
Dextromethorphan has not been banned in India
The Press Information Bureau Fact Check Unit has described claims of an outright ban as misleading. What the Central Drugs Standard Control Organisation restricted is a set of fixed-dose combinations containing dextromethorphan hydrobromide, chiefly those combined with antihistamines and decongestants, with use barred in children below four years.[3] Separately, the fixed-dose combination of chlorpheniramine maleate 2 mg with phenylephrine hydrochloride 5 mg was restricted below four years, with a warning required on the label and package insert.[4] The advisory issued by the Directorate General of Health Services in October 2025 goes further for the paediatric population: cough and cold medications should not be prescribed or dispensed under two years, and are generally not recommended under five.[5]
Dry cough: why the drug class matters more than the brand
A dry, non-productive cough brings nothing up. The stimulus is airway irritation or hyperresponsiveness rather than accumulated secretions, so the class of drug that helps is a centrally acting antitussive, not an expectorant or mucolytic. Giving an expectorant to a cough with nothing to expectorate adds exposure without adding benefit. If your cough is chesty and productive, you are on the wrong page: see wet cough syrups in India and the compositions behind them instead.
Dextromethorphan is the antitussive used in almost every Indian dry-cough formulation. It is a synthetic dextrorotatory morphinan derivative structurally related to levorphanol, and its principal active metabolite is dextrorphan. It is often loosely called a codeine analogue, but it lacks the phenanthrene structure of the classical opioids and has minimal mu-opioid receptor activity. The antitussive mechanism is not fully defined; current evidence points to brainstem pathways regulating the cough reflex, including the nucleus tractus solitarius where vagal afferents terminate, together with sigma-1 receptor agonism.[6]
It is worth being honest about how strong the evidence is. Guideline review of over-the-counter cough medicines as a class found mixed and low-quality evidence, with some suggestion of benefit from a single high dose in adults, other evidence of no effect, and a possible increase in adverse effects.[7] The expected gain is symptom comfort of uncertain size, which is precisely why exposure, sedation and product quality deserve proportionally more weight in the decision than brand reputation does.
The composition decoder: three formulations, many brand names
Select a formulation group to see what it contains, who sedates and who does not, and which regulatory restriction attaches.
Single-ingredient dextromethorphan
One activeNot a fixed-dose combinationLowest interaction surface
The only group in this comparison where the pack contains a single active ingredient. Benadryl DR states dextromethorphan hydrobromide IP 15 mg per 5 ml on the manufacturer’s own product information, with doses spaced every six to eight hours and a stated ceiling of 40 ml in 24 hours for adults and children twelve years and over.[8] Cipla markets a separate single-ingredient Cofsils Dry Cough Syrup alongside its combination variants.[9]
What this group avoids: no antihistamine, so no anticholinergic load and no added sedation from a second active. That does not make it sedation-free. At therapeutic doses, slight drowsiness, dizziness, nausea or vomiting occur in fewer than 10% of patients, and the Indian product information for these packs carries a driving caution.[6][8]
Regulatory position: being a single ingredient, it sits outside the CDSCO restrictions that target dextromethorphan fixed-dose combinations.[3] The Schedule K amendment still applies, so it is dispensed against a prescription.[1]
Dextromethorphan plus chlorpheniramine maleate
Contains a sedating antihistamineFixed-dose combinationRestricted under 4 years
The most common composition in this category, and the one most often mislabelled as non-drowsy in consumer articles. Zedex from Wockhardt and Cofsils DX from Cipla are both chlorpheniramine maleate 2 mg with dextromethorphan hydrobromide 10 mg per 5 ml, and the same composition is marketed by several other companies under different brand names.[9][10]
Chlorpheniramine is the sedating component. It is a first-generation antihistamine that crosses the blood-brain barrier. Its sedative burden is well enough recognised that Indian formulators have run a phase 3 trial specifically replacing it with bilastine, a non-sedating antihistamine, in a dextromethorphan-containing dry-cough syrup.[11] A pack in this group should be treated as sedating regardless of what the marketing copy says.
Regulatory position: a dextromethorphan fixed-dose combination with an antihistamine, so it falls within the group CDSCO restricted below four years of age.[3]
Dextromethorphan plus chlorpheniramine plus phenylephrine
SedatingCardiovascular cautionTriple fixed-dose combination
A three-active combination aimed at cough with nasal congestion and an allergic component. Chericof from Sun Pharmaceutical Industries is phenylephrine 5 mg, chlorpheniramine maleate 2 mg and dextromethorphan hydrobromide 10 mg per 5 ml.[12] Zedex Plus is the same three actives with dextromethorphan at 15 mg.[10]
What the third active adds: phenylephrine is a decongestant, not a cough medicine. It addresses post-nasal drip and nasal blockage where those are genuinely contributing. Where they are not, it is exposure without benefit, and it can be unsuitable where blood pressure or cardiac conditions are present. National advisory guidance asks that multiple-drug combinations be avoided where a single agent will do.[5]
Regulatory position: this group carries two overlapping restrictions below four years, one attaching to the dextromethorphan combination and one to the chlorpheniramine with phenylephrine combination.[3][4]
Composition table: what is verifiably in each pack
Scroll sideways to see every column. Strengths are per 5 ml unless stated.
| Brand | Marketer | Actives per 5 ml | Group | Sedating component | Note |
|---|---|---|---|---|---|
| Benadryl DR | Johnson and Johnson Pvt Ltd, India | DXM HBr 15 mg | A | None present | Manufacturer information states dosing every 6 to 8 hours, not every 4.[8] |
| Cofsils Dry Cough | Cipla | DXM HBr | A | None present | Sugar-free single-ingredient variant, distinct from Cofsils DX.[9] |
| Cofsils DX | Cipla | CPM 2 mg + DXM HBr 10 mg | B | Chlorpheniramine | Same composition as Zedex despite the different brand.[9] |
| Zedex | Wockhardt | CPM 2 mg + DXM HBr 10 mg | B | Chlorpheniramine | Widely listed as non-drowsy in consumer articles. It is not.[10] |
| Zedex Plus | Wockhardt | PE 5 mg + CPM 2 mg + DXM HBr 15 mg | C | Chlorpheniramine | Higher dextromethorphan strength than the base Zedex.[10] |
| Chericof | Sun Pharmaceutical Industries | PE 5 mg + CPM 2 mg + DXM HBr 10 mg | C | Chlorpheniramine | Triple combination for cough with congestion.[12] |
| FTOX-DX | Laafon Galaxy Pharmaceuticals | DXM HBr 10 mg + PE 5 mg + CPM 2 mg | C | Chlorpheniramine | Our own house brand, listed here on the same basis as the rest: it is a sedating triple combination, compositionally equivalent to Chericof. |
| Ascoril LS | Glenmark | Ambroxol 30 mg + Levosalbutamol 1 mg + Guaifenesin 50 mg | Not a dry-cough product | Not applicable | Mucolytic, bronchodilator and expectorant. Indicated for cough with mucus, not dry cough.[13] |
The brand-family trap, from a QA perspective
An Indian cough syrup brand name is a family, not a product. Cofsils covers at least a single-ingredient dry cough syrup, a chlorpheniramine combination sold as Cofsils DX, and a triple combination.[9] Zedex covers a two-active and a three-active variant at different dextromethorphan strengths.[10] Ascoril LS is an expectorant for wet cough and shares its brand root with dry-cough variants.[13]
Any article that lists a brand name without the suffix is not telling you what is in the bottle. Read the composition line on the carton, ingredient by ingredient, and check it against the prescription. That habit matters more than any ranking.
Sedation and driving: check the pack, not the marketing
This is the section the current generation of listicles gets most wrong, and it is the one with a real-world consequence. There is no category of Indian dry-cough syrup that can be described as categorically safe for driving. Make three selections below.
1. What does the composition line on the carton say?
2. What are you doing in the next six hours?
3. What else is already on board?
Make three selections above
This tool reports published cautions. It gives no doses and does not replace the advice of the prescriber or the approved label supplied with your pack.
Governing point will appear here
Interactions that matter more than the brand choice
- Monoamine oxidase inhibitors. Dextromethorphan must not be used with MAOIs such as phenelzine, tranylcypromine, isocarboxazid, selegiline, linezolid or methylene blue. The combination can trigger life-threatening serotonin syndrome, and a 14-day washout is required after stopping an MAOI.[6]
- Other serotonergic drugs. SSRIs, SNRIs, tricyclics, trazodone, mirtazapine, tramadol, lithium, triptans and St John’s wort all raise serotonin syndrome risk through additive effects.[6]
- CYP2D6 inhibitors. This is the interaction most consumer articles omit. Fluoxetine, paroxetine, terbinafine, duloxetine and ritonavir raise dextromethorphan plasma concentrations enough to cause dissociation, hallucinations and CNS toxicity at normal cough-suppressant doses.[6]
- CNS depressants. Alcohol, benzodiazepines, opioids and gabapentinoids give additive CNS and respiratory depression.[6]
- Your own metabolism. CYP2D6 poor metabolisers, reported in roughly 8 to 10% of some populations, show markedly higher systemic exposure and a half-life of about 15 to 20 hours against roughly 2 to 3 hours in extensive metabolisers.[6] Most people never learn which they are, which is a further reason to report an unusually strong or long-lasting effect rather than assume the product is faulty.
Quality: the 2025 contamination cases were not a brand-choice problem
In October 2025 the Central Drugs Standard Control Organisation reported to the World Health Organization the presence of diethylene glycol in oral liquid medicines, and WHO issued a medical product alert naming affected products after clusters of acute illness and child deaths in India.[14] Diethylene glycol and ethylene glycol are industrial solvents with no place in a medicine. Their appearance in a finished syrup is a failure of excipient sourcing and finished-product testing upstream of the pharmacy, and no consumer can test for a contaminant at home.
What a consumer can control is the supply chain and the label: dispensing through a licensed pharmacy against a prescription, a legible batch number, manufacturing date and expiry on both carton and bottle, an identifiable manufacturer name and licence number, an intact tamper-evident seal, and a composition line that matches the prescription. Manufacturers working on the control side of this can follow the systems implications through our CDSCO Revised Schedule M compliance dashboard, and the finished-product testing distinctions in syrup versus suspension: QC tests, limits and GMP rules.
When a dry cough is not a cough syrup problem
- Cough persisting beyond three weeks, which in India also raises the question of tuberculosis.
- Blood in the sputum, chest pain with the cough, or breathlessness at rest.
- Unexplained weight loss, night sweats, or fever that is not settling.
- Hoarseness lasting more than two weeks, or difficulty swallowing.
- A dry cough that started after a new blood-pressure medicine. ACE inhibitor cough is a recognised cause, and suppressing it does not address the trigger.[6]
- Cough with wheeze, or in someone with known asthma or a lung condition.
A chronic cough that does not respond to an antitussive warrants evaluation for gastro-oesophageal reflux disease, upper airway cough syndrome, cough-variant asthma or ACE inhibitor use, rather than a stronger syrup.[6]
Questions readers ask
Yes. Notification G.S.R. 477(E) of 9 June 2026 enacted the Drugs (Fifth Amendment) Rules, 2026 and omitted the word Syrups from item (7) under serial number 13 of Schedule K of the Drugs Rules, 1945. Syrup formulations, including dry cough syrups, are now supplied by licensed pharmacies against a doctor’s prescription. Lozenges were not part of that amendment.
None can be described that way without qualification. Packs containing only dextromethorphan avoid the added sedation of a first-generation antihistamine, but dextromethorphan itself produces slight drowsiness and dizziness in fewer than 10% of patients at therapeutic doses, and Indian product information for these packs carries a driving caution. Packs that also list chlorpheniramine maleate should be treated as sedating, whatever the marketing says.
No. Zedex Cough Syrup from Wockhardt contains chlorpheniramine maleate 2 mg with dextromethorphan hydrobromide 10 mg per 5 ml. Chlorpheniramine is a first-generation sedating antihistamine that crosses the blood-brain barrier, and drowsiness is a recognised effect. Zedex Plus adds phenylephrine and carries dextromethorphan at 15 mg. Several consumer listicles describe Zedex as non-drowsy, which does not match the stated composition.
Ascoril LS from Glenmark contains ambroxol 30 mg, levosalbutamol 1 mg and guaifenesin 50 mg per 5 ml. That is a mucolytic, a bronchodilator and an expectorant, indicated for cough with mucus rather than dry cough. The brand root covers other variants with different compositions, so the suffix on the carton is what determines whether a pack is intended for a productive or a non-productive cough. This is a decision for the prescriber, not for the shelf.
No. The Press Information Bureau Fact Check Unit has described claims of an outright ban as misleading. What the Central Drugs Standard Control Organisation restricted is a set of fixed-dose combinations containing dextromethorphan hydrobromide, mainly those combined with antihistamines and decongestants, barred in children below four years. The molecule itself remains in use, now dispensed against a prescription like every other syrup formulation.
Dextromethorphan is metabolised principally by the CYP2D6 enzyme. People described as poor metabolisers, reported in roughly 8 to 10% of some populations, show markedly higher systemic exposure and a half-life in the region of 15 to 20 hours, against roughly 2 to 3 hours in extensive metabolisers. Certain medicines including fluoxetine, paroxetine, terbinafine, duloxetine and ritonavir inhibit the same enzyme and can produce the same effect. An unusually strong or long-lasting response is worth reporting to your doctor rather than attributing to a faulty batch.
For anyone over twelve months it is a defensible option. Reviewing cough associated with the common cold in patients aged one to eighteen, an expert panel found honey may give greater relief than no treatment, diphenhydramine or placebo, while not being more effective than dextromethorphan. Honey must never be given below twelve months because of botulism risk. Since a prescription is required for syrup formulations in any case, the consultation is the necessary step rather than the choice between the two.
Most coughs settle without treatment within about three weeks. A cough persisting beyond that, or accompanied by blood in the sputum, chest pain, breathlessness, unexplained weight loss, night sweats or persistent fever, needs assessment rather than continued suppression. A chronic cough that does not respond to an antitussive warrants evaluation for reflux disease, upper airway cough syndrome, cough-variant asthma or ACE inhibitor use.
Related guides on Laafon
A regulatory or formulation question about oral liquids?
Laafon Galaxy Pharmaceuticals advises on pharmaceutical quality, regulatory affairs and manufacturing compliance. For clinical advice about your own cough, please consult a registered medical practitioner.
References
- Ministry of Health and Family Welfare, Government of India. Notification G.S.R. 477(E), Drugs (Fifth Amendment) Rules, 2026: removal of the syrup exemption under Schedule K of the Drugs Rules, 1945. 9 June 2026. Regulatory summary available from: cliniexperts.com. Accessed August 2026.
- India ends over-the-counter sale of cough syrups without prescription: what new rules say. ThePrint; 2026. Available from: theprint.in. Accessed August 2026.
- Press Information Bureau Fact Check Unit. Government dismisses rumours of ban on dextromethorphan cough syrups. Reported by News on AIR; 2025. Available from: newsonair.gov.in. Accessed August 2026.
- India’s drug regulator bans anti-cold syrup for under-4 children. The Tribune; 2023. Reporting the CDSCO restriction on the fixed-dose combination of chlorpheniramine maleate IP 2 mg with phenylephrine hydrochloride IP 5 mg. Available from: tribuneindia.com. Accessed August 2026.
- Ministry of Health and Family Welfare, Government of India. Union Health Secretary chairs high-level meeting with States and UTs on quality and rational use of cough syrups, referencing the Directorate General of Health Services advisory on rational use of cough syrups. Press Information Bureau; 2025. Available from: pib.gov.in. Accessed August 2026.
- Oh SR, Sabir S, Patel P, Taylor A. Dextromethorphan. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; updated 13 December 2025. Available from: ncbi.nlm.nih.gov. Accessed August 2026.
- National Institute for Health and Care Excellence. Cough (acute): antimicrobial prescribing. NICE guideline NG120, summary of the evidence. London: NICE; 2019. Available from: nice.org.uk. Accessed August 2026.
- Benadryl India. Important product information: Benadryl Dry Cough Active Relief, dextromethorphan hydrobromide IP 15 mg per 5 ml. Available from: benadryl.co.in. Accessed August 2026.
- Cipla. Cofsils product range: Cofsils Dry Cough Syrup and Cofsils DX Cough Syrup. Available from: cofsils.com. Accessed August 2026.
- Wockhardt. Zedex Cough Syrup and Zedex Plus Cough Syrup product listings. Available from: wockhardtepharmacy.com. Accessed August 2026.
- Efficacy of bilastine, dextromethorphan and phenylephrine syrup in patients with dry cough: a phase 3 randomised trial. PubMed Central; 2024. Comparator arm was chlorpheniramine maleate 4 mg with dextromethorphan 20 mg and phenylephrine 10 mg per 10 ml. Available from: ncbi.nlm.nih.gov. Accessed August 2026.
- Chericof Syrup, Sun Pharmaceutical Industries: phenylephrine 5 mg, chlorpheniramine maleate 2 mg and dextromethorphan hydrobromide 10 mg per 5 ml. PharmEasy product monograph. Available from: pharmeasy.in. Accessed August 2026.
- Ascoril LS Syrup, Glenmark Pharmaceuticals: ambroxol 30 mg, levosalbutamol 1 mg and guaifenesin 50 mg per 5 ml, indicated for cough with mucus. Tata 1mg product monograph. Available from: 1mg.com. Accessed August 2026.
- World Health Organization. Medical Product Alert No. 5/2025: substandard (contaminated) oral liquid medicines. Geneva: WHO; 13 October 2025. Available from: who.int. Accessed August 2026.
This page is educational and is not a diagnosis, a prescription, or a substitute for clinical assessment. It recommends no brand and states no doses. Compositions are reported from manufacturer and product-monograph sources current at the time of writing and can change between batches and pack variants: always read the composition line on the pack you actually hold. Indian statutory instruments and pharmacopoeial texts change frequently, and the regulatory positions summarised here reflect the sources listed above. Verify current status with a registered medical practitioner or pharmacist before acting.
